纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | EIF4A2 |
Uniprot No | Q14240 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-407aa |
氨基酸序列 | MSGGSADYNREHGGPEGMDPDGVIESNWNEIVDNFDDMNLKESLLRGIYAYGFEKPSAIQQRAIIPCIKGYDVIAQAQSGTGKTATFAISILQQLEIEFKETQALVLAPTRELAQQIQKVILALGDYMGATCHACIGGTNVRNEMQKLQAEAPHIVVGTPGRVFDMLNRRYLSPKWIKMFVLDEADEMLSRGFKDQIYEIFQKLNTSIQVVLLSATMPTDVLEVTKKFMRDPIRILVKKEELTLEGIKQFYINVEREEWKLDTLCDLYETLTITQAVIFLNTRRKVDWLTEKMHARDFTVSALHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGRFGRKGVAINFVTEEDKRILRDIETFYNTTVEEMPMNVADLI |
预测分子量 | 73.4kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF4A2重组蛋白的模拟参考文献示例(基于领域内常见研究方向,建议通过PubMed或Google Scholar查找最新文献验证):
---
1. **标题**: "EIF4A2 regulates global protein synthesis by controlling ribosomal RNA stability"
**作者**: Smith J, et al.
**摘要**: 研究通过重组EIF4A2蛋白发现其通过结合特定RNA结构域调控rRNA加工,影响核糖体生物合成和细胞翻译效率,提示其在癌症细胞增殖中的潜在作用。
2. **标题**: "Structural insights into the RNA helicase activity of EIF4A2 using recombinant protein crystallography"
**作者**: Lee H, et al.
**摘要**: 利用重组EIF4A2蛋白进行X射线晶体学分析,揭示其ATP依赖的RNA解旋酶活性机制,为靶向EIF4A2的抗癌药物设计提供结构基础。
3. **标题**: "EIF4A2 interacts with eIF4E to modulate mRNA translation initiation in stress conditions"
**作者**: Zhang Y, et al.
**摘要**: 通过重组蛋白互作实验,证明EIF4A2在细胞应激条件下与eIF4E形成复合物,选择性抑制特定mRNA的翻译,参与细胞应激反应调控。
4. **标题**: "Recombinant EIF4A2 overexpression promotes tumorigenesis via mTOR signaling in glioblastoma"
**作者**: Wang R, et al.
**摘要**: 在胶质母细胞瘤模型中,重组EIF4A2的过表达通过激活mTOR通路增强肿瘤细胞侵袭性,提示其作为治疗靶点的可能性。
---
建议通过以下关键词在学术数据库中检索具体文献:**EIF4A2 recombinant protein**、**EIF4A2 RNA helicase**、**EIF4A2 cancer**。
**Background of EIF4A2 Recombinant Protein**
Eukaryotic Initiation Factor 4A2 (EIF4A2) is a member of the DEAD-box RNA helicase family, playing a critical role in translation initiation by unwinding secondary structures in mRNA to facilitate ribosome binding. As a component of the eIF4F complex, it collaborates with eIF4E and eIF4G to regulate cap-dependent translation, a process essential for protein synthesis. Unlike its paralog EIF4A1. EIF4A2 is ubiquitously expressed and implicated in both canonical translation and specialized regulatory mechanisms, such as microRNA-mediated repression and stress-adaptive translational shutdown.
Dysregulation of EIF4A2 is linked to pathologies including cancer, neurodegeneration, and viral infections, highlighting its therapeutic potential. Recombinant EIF4A2 proteins are engineered to study its helicase activity, structure-function relationships, and interactions with translational machinery or inhibitors. These proteins are typically produced via heterologous expression in *E. coli* or mammalian systems, followed by affinity purification to ensure high purity and functionality. Tagged variants (e.g., His-tag, GST-tag) enable applications in pull-down assays, crystallography, or drug screening.
Recent studies leverage recombinant EIF4A2 to explore small-molecule inhibitors (e.g., rocaglates) that clamp EIF4A2 onto RNA, selectively suppressing oncogene translation. Its recombinant form also aids in deciphering stress granule dynamics and viral translation hijacking mechanisms. Overall, EIF4A2 recombinant tools are pivotal for advancing translational control research and developing targeted therapies.
×